HC Wainwright Comments on CG Oncology FY2030 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for shares of CG Oncology in a research note issued to investors on Monday, January 26th. HC Wainwright analyst A. Maldonado expects that the company will earn $4.42 per share for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.57) EPS for the quarter, meeting analysts’ consensus estimates of ($0.57). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.07 million.

A number of other analysts have also recently weighed in on CGON. Piper Sandler increased their price objective on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Guggenheim began coverage on shares of CG Oncology in a research report on Tuesday, October 7th. They issued a “buy” rating and a $90.00 price objective on the stock. Royal Bank Of Canada upped their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Wall Street Zen raised shares of CG Oncology from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $82.00 price target on shares of CG Oncology in a report on Monday, January 12th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.83.

CG Oncology Stock Up 3.4%

NASDAQ CGON opened at $55.10 on Wednesday. The firm has a market cap of $4.44 billion, a P/E ratio of -27.01 and a beta of 1.35. CG Oncology has a 52-week low of $14.80 and a 52-week high of $57.88. The business’s 50-day moving average price is $44.90 and its 200 day moving average price is $37.78.

Insider Activity at CG Oncology

In other CG Oncology news, Director James Mulay sold 11,145 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction on Monday, November 17th. The stock was sold at an average price of $41.43, for a total value of $41,430.00. Additional details regarding this sale are available in the official SEC disclosure.

Hedge Funds Weigh In On CG Oncology

Several hedge funds have recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CG Oncology during the 4th quarter worth approximately $27,000. Winthrop Capital Management LLC purchased a new position in CG Oncology during the second quarter worth $38,000. Strengthening Families & Communities LLC acquired a new position in shares of CG Oncology in the third quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of CG Oncology by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after acquiring an additional 398 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of CG Oncology by 15.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after acquiring an additional 433 shares during the last quarter. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.